NASDAQ:MRTX - Mirati Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $142.43
  • Forecasted Upside: 100.10 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▲ +4.05 (6.03%)

This chart shows the closing price for MRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mirati Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRTX

Analyst Price Target is $142.43
▲ +100.10% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is $142.43, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 100.10% upside from the last price of $71.18.

This chart shows the closing price for MRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 investment analysts is to buy stock in Mirati Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/9/2022OppenheimerLower Price Target$85.00Low
6/7/2022BMO Capital MarketsReiterated RatingBuy$80.00High
6/7/2022The Goldman Sachs GroupLower Price TargetBuy$216.00 ➝ $188.00High
6/7/2022Stifel NicolausBoost Price Target$105.00 ➝ $111.00High
6/7/2022JMP SecuritiesUpgradeMarket Perform ➝ Outperform$72.00High
6/4/2022JonestradingReiterated RatingBuy$100.00Low
5/27/2022SVB LeerinkLower Price TargetOutperform$164.00 ➝ $111.00High
5/24/2022The Goldman Sachs GroupLower Price TargetBuy$253.00 ➝ $216.00Low
5/20/2022GuggenheimUpgradeNeutral ➝ Buy$115.00High
5/5/2022CitigroupLower Price Target$227.00 ➝ $208.00High
3/2/2022CitigroupLower Price TargetBuy$244.00 ➝ $227.00Medium
3/1/2022Stifel NicolausLower Price TargetBuy$150.00 ➝ $118.00Low
3/1/2022Morgan StanleyLower Price TargetEqual Weight$150.00 ➝ $140.00Low
3/1/2022BMO Capital MarketsLower Price Target$187.00 ➝ $130.00High
2/18/2022OppenheimerLower Price Target$175.00 ➝ $155.00Low
2/8/2022SVB LeerinkReiterated RatingOutperformHigh
2/1/2022Morgan StanleyLower Price TargetEqual Weight$175.00 ➝ $150.00Low
2/1/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$171.00 ➝ $141.00High
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$187.00Low
9/22/2021Stifel NicolausInitiated CoverageBuy$202.00Medium
9/22/2021CitigroupBoost Price TargetBuy$232.00 ➝ $244.00Low
9/21/2021Morgan StanleyBoost Price TargetEqual Weight$160.00 ➝ $173.00High
9/21/2021SVB LeerinkBoost Price TargetOutperform$195.00 ➝ $205.00High
9/21/2021OppenheimerBoost Price TargetMarket Perform$160.00 ➝ $175.00High
9/20/2021Jefferies Financial GroupInitiated CoverageBuy$193.00High
9/19/2021SVB LeerinkReiterated RatingBuyHigh
9/7/2021JPMorgan Chase & Co.Lower Price TargetOverweight$205.00 ➝ $203.00Low
8/26/2021Morgan StanleyInitiated CoverageEqual Weight$160.00High
8/9/2021HC WainwrightLower Price TargetBuy$251.00 ➝ $247.00High
6/4/2021CitigroupUpgradeNeutral ➝ BuyLow
5/24/2021OppenheimerReiterated RatingOutperform ➝ Market Perform$245.00 ➝ $160.00Medium
5/17/2021OppenheimerDowngradeOutperform ➝ Market Perform$245.00 ➝ $160.00Low
5/10/2021HC WainwrightLower Price TargetBuy$255.00 ➝ $251.00Medium
5/10/2021Jefferies Financial GroupUpgradeHold ➝ Buy$208.00 ➝ $196.00Medium
3/1/2021OppenheimerLower Price TargetOutperform$260.00 ➝ $255.00Low
3/1/2021HC WainwrightLower Price TargetBuy$257.00 ➝ $255.00Low
1/15/2021HC WainwrightLower Price TargetBuy$265.00 ➝ $257.00Low
12/16/2020Credit Suisse GroupBoost Price TargetOutperform$225.00 ➝ $285.00Low
12/8/2020Evercore ISIInitiated CoverageOutperformMedium
12/8/2020JMP SecuritiesInitiated CoverageMarket PerformMedium
11/17/2020Bank of AmericaDowngradeNeutral ➝ Underperform$196.00Low
11/10/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$206.00 ➝ $208.00Low
11/10/2020GuggenheimDowngradeBuy ➝ Neutral$230.00Low
11/9/2020HC WainwrightBoost Price TargetBuy$233.00 ➝ $265.00Medium
11/5/2020OppenheimerBoost Price Target$225.00 ➝ $260.00Low
11/5/2020Piper SandlerBoost Price TargetOverweight$210.00 ➝ $260.00Medium
11/2/2020HC WainwrightLower Price TargetBuy$238.00 ➝ $233.00Low
10/29/2020BarclaysBoost Price TargetOverweight$143.00 ➝ $244.00High
10/27/2020Credit Suisse GroupBoost Price TargetOutperform$190.00 ➝ $225.00High
10/26/2020OppenheimerBoost Price TargetOutperform$190.00 ➝ $225.00High
10/26/2020SVB LeerinkBoost Price TargetOutperform$134.00 ➝ $195.00High
10/26/2020The Goldman Sachs GroupBoost Price TargetBuy$152.00 ➝ $267.00High
10/26/2020HC WainwrightBoost Price TargetBuy$222.00 ➝ $238.00High
10/26/2020Piper SandlerBoost Price TargetOverweight$170.00 ➝ $210.00High
10/21/2020BMO Capital MarketsBoost Price TargetMarket Perform$101.00 ➝ $176.00High
10/16/2020HC WainwrightBoost Price TargetBuy$185.00 ➝ $222.00High
10/8/2020CSFBBoost Price TargetOutperform$140.00 ➝ $190.00Medium
10/8/2020Credit Suisse GroupBoost Price TargetOutperform$140.00 ➝ $190.00Medium
9/28/2020Bank of AmericaInitiated CoverageNeutral$172.00Low
9/21/2020OppenheimerBoost Price TargetOutperform$133.00 ➝ $190.00Low
9/21/2020Piper SandlerBoost Price TargetOverweight$145.00 ➝ $170.00Low
9/18/2020CitigroupDowngradeBuy ➝ Neutral$127.00 ➝ $183.00Medium
9/17/2020HC WainwrightBoost Price TargetBuy$163.00 ➝ $185.00High
8/10/2020OppenheimerBoost Price Target$105.00 ➝ $133.00Medium
8/10/2020HC WainwrightReiterated RatingBuy$163.00Medium
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$135.00 ➝ $140.00Medium
8/7/2020BarclaysBoost Price TargetOverweight$123.00 ➝ $143.00Medium
7/29/2020Credit Suisse GroupBoost Price TargetOutperform$115.00 ➝ $135.00Medium
5/1/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$116.00High
4/16/2020The Goldman Sachs GroupInitiated CoverageBuy$151.00High
3/30/2020OppenheimerLower Price TargetOutperform$129.00 ➝ $105.00High
3/12/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$88.00High
2/28/2020HC WainwrightReiterated RatingBuy$134.00 ➝ $126.00High
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$101.00Low
1/24/2020HC WainwrightReiterated RatingBuy$117.00 ➝ $134.00Medium
1/7/2020CowenReiterated RatingBuyHigh
11/5/2019GuggenheimBoost Price TargetBuy$116.00 ➝ $128.00Low
10/29/2019Cantor FitzgeraldBoost Price TargetNeutral$81.00 ➝ $85.00High
10/18/2019CowenReiterated RatingBuyLow
10/17/2019HC WainwrightReiterated RatingBuyHigh
10/9/2019CitigroupSet Price TargetBuy$130.00Low
9/27/2019Credit Suisse GroupSet Price TargetPositive ➝ Buy$120.00 ➝ $115.00Low
9/24/2019GuggenheimUpgradeNeutral ➝ Buy$116.00High
9/11/2019B. RileyLower Price TargetNeutral$92.00 ➝ $83.00High
9/9/2019Cantor FitzgeraldLower Price TargetNeutral$85.00 ➝ $81.00High
9/9/2019Jefferies Financial GroupUpgradeHold ➝ Buy$89.00 ➝ $105.00Medium
8/6/2019HC WainwrightReiterated RatingBuy$117.00High
8/6/2019CowenReiterated RatingBuyHigh
8/2/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$101.00 ➝ $85.00High
7/31/2019SVB LeerinkSet Price TargetBuy$118.00High
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ Hold$86.00Medium
7/12/2019JPMorgan Chase & Co.Boost Price TargetNeutral$70.00 ➝ $101.00Low
6/19/2019B. RileyDowngradeBuy ➝ Neutral$60.00 ➝ $92.00Medium
6/7/2019GuggenheimDowngradeBuy ➝ Neutral$95.56Medium
6/5/2019HC WainwrightReiterated RatingBuy ➝ Buy$84.00 ➝ $117.00Low
6/5/2019BarclaysBoost Price TargetOverweight$85.00 ➝ $123.00Low
6/4/2019SunTrust BanksBoost Price TargetBuy$120.00Medium
6/4/2019Piper Jaffray CompaniesBoost Price TargetOverweight$85.00 ➝ $125.00Medium
6/4/2019CowenReiterated RatingBuyHigh
6/4/2019Cantor FitzgeraldBoost Price TargetNeutral ➝ Positive$66.00 ➝ $85.00High
6/4/2019CitigroupUpgradeNeutral ➝ Buy$76.00 ➝ $132.00High
5/16/2019Cantor FitzgeraldReiterated RatingHoldHigh
5/15/2019CowenReiterated RatingBuyHigh
5/1/2019Cantor FitzgeraldReiterated RatingHold$66.00High
4/17/2019JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$72.00High
4/2/2019Cantor FitzgeraldSet Price TargetHold$66.00Low
3/25/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$85.00Medium
3/19/2019OppenheimerReiterated RatingBuyMedium
3/13/2019CowenReiterated RatingBuyHigh
3/7/2019OppenheimerSet Price TargetBuy$81.00Low
3/4/2019Cantor FitzgeraldInitiated CoverageNeutral$66.00Medium
3/4/2019CitigroupBoost Price TargetBuy ➝ Neutral$64.00 ➝ $77.00Low
2/15/2019SVB LeerinkReiterated RatingOutperformHigh
2/15/2019HC WainwrightReiterated RatingBuyMedium
2/15/2019Piper Jaffray CompaniesInitiated CoverageOverweight$85.00Medium
1/16/2019OppenheimerBoost Price TargetOutperform$57.00 ➝ $65.00High
11/30/2018B. RileyInitiated CoverageBuy ➝ Buy$60.00Low
11/15/2018Jefferies Financial GroupReiterated RatingHold$37.00High
11/12/2018HC WainwrightReiterated RatingBuy$65.00High
11/11/2018OppenheimerSet Price TargetBuy$57.00Medium
10/30/2018OppenheimerSet Price TargetBuy$62.00Low
10/29/2018GuggenheimUpgradeNeutral ➝ BuyLow
10/22/2018CowenReiterated RatingBuyHigh
9/27/2018CowenReiterated RatingBuyHigh
9/17/2018GuggenheimInitiated CoverageNeutralLow
7/20/2018HC WainwrightBoost Price TargetBuy$63.00High
7/9/2018OppenheimerBoost Price TargetOutperform$35.00 ➝ $62.00High
7/5/2018CitigroupBoost Price TargetBuy$37.00 ➝ $64.00Medium
6/28/2018CowenReiterated RatingBuyMedium
6/19/2018SunTrust BanksBoost Price TargetBuy$60.00Medium
3/12/2018HC WainwrightBoost Price TargetBuy$40.00High
3/12/2018BarclaysInitiated CoverageOverweight$44.00High
3/9/2018SunTrust BanksBoost Price TargetPositive ➝ Buy$40.00High
3/5/2018CitigroupBoost Price TargetBuy ➝ Buy$23.00 ➝ $37.00High
1/9/2018HC WainwrightBoost Price TargetBuy ➝ Buy$17.00 ➝ $21.00N/A
1/8/2018OppenheimerSet Price TargetBuy$18.00High
12/21/2017CowenInitiated CoverageOutperformLow
11/22/2017OppenheimerReiterated RatingBuy$18.00N/A
11/14/2017HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $17.00N/A
11/14/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$9.00N/A
11/7/2017HC WainwrightReiterated RatingBuyN/A
10/12/2017SunTrust BanksReiterated RatingBuy$13.00N/A
10/12/2017HC WainwrightReiterated RatingBuy ➝ Buy$20.00N/A
10/2/2017SunTrust BanksReiterated RatingBuy$13.00High
9/19/2017CIBCInitiated CoverageOutperform ➝ Outperform$18.00Low
9/19/2017CitigroupReiterated RatingBuy$8.00 ➝ $16.00Low
9/18/2017OppenheimerInitiated CoverageOutperform$18.00Medium
9/15/2017SVB LeerinkBoost Price TargetMkt Perform ➝ Market Perform$7.00 ➝ $9.00N/A
8/4/2017Jefferies Financial GroupSet Price TargetHold$5.00Low
(Data available from 7/3/2017 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
  • 4 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 4 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mirati Therapeutics logo
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $71.18
Low: $66.49
High: $71.24

50 Day Range

MA: $57.82
Low: $39.16
High: $71.18

52 Week Range

Now: $71.18
Low: $32.96
High: $195.99


849,436 shs

Average Volume

2,204,780 shs

Market Capitalization

$3.95 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Mirati Therapeutics?

The following Wall Street analysts have issued research reports on Mirati Therapeutics in the last twelve months: Bank of America Co., BMO Capital Markets, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Jonestrading, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Stifel Nicolaus,, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for MRTX.

What is the current price target for Mirati Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Mirati Therapeutics in the last year. Their average twelve-month price target is $142.43, suggesting a possible upside of 100.1%.
View the latest price targets for MRTX.

What is the current consensus analyst rating for Mirati Therapeutics?

Mirati Therapeutics currently has 3 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRTX will outperform the market and that investors should add to their positions of Mirati Therapeutics.
View the latest ratings for MRTX.

How do I contact Mirati Therapeutics' investor relations team?

Mirati Therapeutics' physical mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 332-3410 and its investor relations email address is [email protected] The official website for Mirati Therapeutics is Learn More about contacing Mirati Therapeutics investor relations.